BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

規制と法律 · 2019/9/271 分で読めます

Prospective Grant of Exclusive Patent License: Capsid-Free AAV Vectors, Compositions, and Methods for Vector Production and Gene Delivery

ローカル自動翻訳 · 情報源の原言語

概要

The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Generation Bio Co. ("Generation Bio"), a company based in Cambridge, Massachusetts (in the exclusive field specified below), and a co- exclusive license to Generation Bio and Spark Therapeutics, a company based in Philadelphia, Pennsylvania (in the co-exclusive field specified below), to practice the inventions embodied in the patent application listed in the Supplementary Information section of this notice.

情報源の原言語: Federal Register — All Documents原文の発表を開く →

関連インサイト

ビジネスインサイト →